Cardiac safety of liposomal anthracyclines.
Anthracyclines remain amongst the most active therapeutic agents for breast cancer treatment. Rather than being supplanted by novel targeted agents, they are being combined with them in various schedules. Furthermore, anthracyclines themselves are still being studied, with increasing biological understanding of their biological activity and molecular targets. A cardiac safe formulation of doxorubicin opens a number of interesting therapeutic opportunities. Liposomal doxorubicins appear to provide this opportunity.
Batist
Gerald
G
The Montreal Center for Experimental Therapeutics in Cancer, Lady Davis Institute for Medical Research, The Sir Mortimer B Davis-Jewish General Hospital, McGill University, Montreal, QC, Canada. gerald.batist@mcgill.ca
D000328:Adult; D000368:Aged; D018943:Anthracyclines / Q000008:administration & dosage* / Q000009:adverse effects*; D000903:Antibiotics, Antineoplastic / Q000008:administration & dosage* / Q000009:adverse effects*; D017322:Clinical Trials, Phase II as Topic; D004317:Doxorubicin / Q000008:administration & dosage / Q000009:adverse effects; D005079:Excipients; D005260:Female; D006331:Heart Diseases / Q000139:chemically induced* / Q000473:pathology; D006801:Humans; D008081:Liposomes; D008297:Male; D008875:Middle Aged; D011092:Polyethylene Glycols
D018943:Anthracyclines; D000903:Antibiotics, Antineoplastic; D005079:Excipients; D008081:Liposomes; D011092:Polyethylene Glycols; D004317:Doxorubicin